Au, Switzerland

Stefan Warmuth

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.8

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Stefan Warmuth

Introduction

Stefan Warmuth is a notable inventor based in Au, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 2 patents, his work focuses on innovative therapeutic solutions.

Latest Patents

Warmuth's latest patents include groundbreaking inventions. The first patent is for "Antibodies targeting CD137 and methods of use thereof." This invention relates to an isolated antibody that specifically binds human CD137, along with pharmaceutical compositions and methods of use. It also encompasses a nucleic acid that encodes the antibody, a vector containing the nucleic acid, and a method for producing the antibody. The second patent is for a "Multispecific antibody comprising CD137 binding domain and PDL1 binding domain." This invention involves a multispecific antibody that includes at least one CD137 binding domain and one PDL1 binding domain, along with related pharmaceutical compositions and methods of use.

Career Highlights

Stefan Warmuth is currently associated with Numab Therapeutics AG, where he continues to advance his research and development efforts. His work at Numab Therapeutics AG focuses on creating innovative therapeutic antibodies that can address various medical challenges.

Collaborations

Warmuth collaborates with talented professionals in his field, including Tea Gunde and Matthias Brock. These collaborations enhance the research and development process, leading to more effective solutions in biotechnology.

Conclusion

Stefan Warmuth's contributions to the field of biotechnology through his patents and work at Numab Therapeutics AG highlight his commitment to innovation. His inventions in antibody development are paving the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…